Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17038967 | 0.93 | MAPT (0.49) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL17038968 | 0.90 | HTT (0.50) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL17039013 | 0.89 | RXFP1 (0.47) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL17039024 | 0.88 | HDAC1 (0.51) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL17038866 | 0.88 | SMN1; SMN2 (0.54) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL17195547 | 0.87 | HTT (0.56) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL17039011 | 0.87 | POLB (0.55) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL17039017 | 0.86 | MEN1 (0.52) | MAPTALDH1A1HTTSMN1; SMN2NPSR1 | |
| SCHEMBL17199331 | 0.86 | ALDH1A1 (0.45) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL17038855 | 0.86 | RXFP1 (0.49) | MAPTALDH1A1HTTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3107902-B1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIV CORNELL CENTER FOR TECHNOLOGY ENTERPRISE & COMMERCIALIZATION CCTEC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY | 2020-11-12 | — | — | US | disclosed |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| WO-2019104067-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY (US) | 2019-05-31 | — | — | WO | disclosed |
| US-10227345-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180215757-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2018-08-02 | — | — | US | disclosed |
| US-9850243-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-10227345-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | MAPT 1951/4885ALDH1A1 1799/4885HTT 4625/4885 |
| US-20180215757-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | MAPT 1951/4885ALDH1A1 1799/4885HTT 4625/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | MAPT 1951/4885ALDH1A1 1799/4885HTT 4625/4885 |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | MAPT 352/4885ALDH1A1 3976/4885HTT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.